Stem Cell Injection in Cancer Survivors

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

November 30, 2019

Study Completion Date

April 20, 2020

Conditions
Cardiomyopathy Due to Anthracyclines
Interventions
BIOLOGICAL

Allo-MSCs

20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

BIOLOGICAL

Placebo

20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

Trial Locations (7)

32610

University of Florida-Department of Medicine, Gainesville

33101

University of Miami-Interdiciplinary Stem Cell Institute, Miami

40202

University of Louisville, Louisville

46202

Indiana Center for Vascular Biology and Medicine, Indianapolis

55407

Minneapolis Heart Institute Foundation, Minneapolis

77030

Texas Heart Institute, Houston

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

The University of Texas Health Science Center, Houston

OTHER

NCT02509156 - Stem Cell Injection in Cancer Survivors | Biotech Hunter | Biotech Hunter